NetSig: network-based discovery from cancer genomes
暂无分享,去创建一个
Joshua D. Campbell | Candace R. Chouinard | W. Hahn | G. Getz | M. Lawrence | K. Lage | H. Horn | Y. Shrestha | J. Hu | Elizabeth Worstell | E. Shea | N. Ilić | E. Kim | A. Kamburov | A. Kashani | J. Boehm | J. Campbell | Eejung Kim | J. X. Hu | C. Chouinard | Alireza Kashani
[1] Steve D. M. Brown,et al. Defective myosin VIIA gene responsible for Usher syndrome type IB , 1995, Nature.
[2] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[3] Anthony E. Reeve,et al. E-cadherin germline mutations in familial gastric cancer , 1998, Nature.
[4] U. Wolfrum,et al. Vezatin, a novel transmembrane protein, bridges myosin VIIA to the cadherin–catenins complex , 2000, The EMBO journal.
[5] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[6] M. Maniak,et al. Cell adhesion: Ushering in a new understanding of myosin VII , 2001, Current Biology.
[7] Toshio Kuroki,et al. Role of Smad4 (DPC4) inactivation in human cancer. , 2003, Biochemical and biophysical research communications.
[8] Min Wu,et al. Expression of cell cycle/growth regulator genes in human hepatocellular carcinoma and adjacent normal liver tissues. , 2003, Oncology reports.
[9] C. Hill,et al. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. , 2004, The Biochemical journal.
[10] R. Bast,et al. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. , 2006, Methods in enzymology.
[11] Pall I. Olason,et al. A human phenome-interactome network of protein complexes implicated in genetic disorders , 2007, Nature Biotechnology.
[12] Eric S. Lander,et al. Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.
[13] Francisco S. Roque,et al. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes , 2008, Proceedings of the National Academy of Sciences.
[14] C. Yeang,et al. Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] C. Sander,et al. Functional Copy-Number Alterations in Cancer , 2008, PloS one.
[16] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[17] Christopher A. Miller,et al. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors , 2011, BMC Medical Genomics.
[18] M. Daly,et al. Proteins Encoded in Genomic Regions Associated with Immune-Mediated Disease Physically Interact and Suggest Underlying Biology , 2011, PLoS genetics.
[19] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[20] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[21] T. Schlomm,et al. Transcription alterations of members of the ubiquitin–proteasome network in prostate carcinoma , 2011, Prostate Cancer and Prostatic Diseases.
[22] Eli Upfal,et al. Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.
[23] D. Bar-Sagi,et al. RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.
[24] T. Nakazawa,et al. Transcription factor Runx2 is a regulator of epithelial–mesenchymal transition and invasion in thyroid carcinomas , 2012, Laboratory Investigation.
[25] A. Gonzalez-Perez,et al. Functional impact bias reveals cancer drivers , 2012, Nucleic acids research.
[26] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[27] Martha L Slattery,et al. MAP kinase genes and colon and rectal cancer. , 2012, Carcinogenesis.
[28] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[29] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[30] D. Bae,et al. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival , 2012, British Journal of Cancer.
[31] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[32] Takashi Suzuki,et al. Runt‐related transcription factor 2 in human colon carcinoma: A potent prognostic factor associated with estrogen receptor , 2012, International journal of cancer.
[33] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[34] Gabor T. Marth,et al. Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics , 2013, Science.
[35] Andrew M. Gross,et al. Network-based stratification of tumor mutations , 2013, Nature Methods.
[36] J. Mesirov,et al. β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2013, Cell.
[37] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[38] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[39] E. Lander,et al. Lessons from the Cancer Genome , 2013, Cell.
[40] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[41] X. Miao,et al. NT5E and FcGBP as key regulators of TGF-1-induced epithelial–mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer , 2013, Cell and Tissue Research.
[42] David Tamborero,et al. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..
[43] D. Beer,et al. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. , 2014, The Journal of clinical investigation.
[44] C. Rommel,et al. PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.
[45] S. Gabriel,et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.
[46] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[47] Peilin Jia,et al. VarWalker: Personalized Mutation Network Analysis of Putative Cancer Genes from Next-Generation Sequencing Data , 2014, PLoS Comput. Biol..
[48] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[49] W. Hahn,et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene , 2014, Proceedings of the National Academy of Sciences.
[50] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[51] Benjamin J. Raphael,et al. Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.
[52] Pradip De,et al. MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. , 2015, American journal of cancer research.
[53] S. Cook,et al. Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome , 2015, Cellular and Molecular Life Sciences.
[54] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[55] C. Sander,et al. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014, Genome Biology.
[56] Todd R. Golub,et al. An ecosystem of cancer cell line factories to support a cancer dependency map , 2015, Nature Reviews Genetics.
[57] Gary D Bader,et al. Pathway and network analysis of cancer genomes , 2015, Nature Methods.
[58] Pablo Tamayo,et al. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. , 2016, Cancer discovery.
[59] S. K. Zaidi,et al. Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer. , 2016, Endocrinology.
[60] Angela N. Brooks,et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.
[61] Jianxing He,et al. Identification of TRPCs genetic variants that modify risk for lung cancer based on the pathway and two-stage study , 2016, Meta gene.
[62] Chandra Sekhar Pedamallu,et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.
[63] F. Supek,et al. MUFFINN: cancer gene discovery via network analysis of somatic mutation data , 2016, Genome Biology.
[64] Daniel Marbach,et al. Tissue-specific regulatory circuits reveal variable modular perturbations across complex diseases , 2016, Nature Methods.
[65] S. Brunak,et al. A scored human protein–protein interaction network to catalyze genomic interpretation , 2017, Nature Methods.
[66] S. Chakrabarti,et al. Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. , 2017, Biochimica et biophysica acta. General subjects.